Therefore, the therapeutic success of targeting the HIF-1α-mTOR pathway may depend on precise timing to maximize its efficacy, underscoring the importance of understanding microglial metabolic transitions across different disease stages for the development of effective immunometabolic interventions in AD. The gene discussed is HIF1A; the disease is Alzheimer disease.